Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp

Table 3 Univariate logistic regression analysis

			OR	95%CI for OR		P value
				Lower	Upper
Gender			2.30	1.07	4.94	0.033a
Head site			4.07	1.53	10.83	0.005a
Max values	LSR composite		1.55	1.27	1.89	< 0.001a
		Erythema	3.90	1.86	8.19	< 0.001a
		Crusting	1.85	1.18	2.92	0.008a
		Swelling	2.24	1.50	3.35	< 0.001a
		Vesiculation/pustulation	2.76	1.55	4.94	0.001a
Day 2	LSR composite		1.70	1.36	2.12	< 0.001a
		Erythema	3.83	2.05	7.17	< 0.001a
		Vesiculation/pustulation	2.82	1.74	4.56	< 0.001a
		Swelling	2.73	1.64	4.55	< 0.001a
Day 3	LSR composite		1.65	1.34	2.05	< 0.001a
		Erythema	3.90	1.86	8.19	< 0.001a
		Vesiculation/pustulation	2.76	1.55	4.94	0.001a
		Swelling	2.22	1.51	3.28	< 0.001a
		Ulceration	1.72	1.06	2.79	0.028a
Day 8	LSR composite		1.25	1.07	1.47	0.006a
		Erythema	2.44	1.45	4.13	0.001a
		Swelling	1.55	1.06	2.25	0.022a
		Crusting	1.76	1.17	2.64	0.006a
Day 15	LSR composite		1.27	1.02	1.59	0.030a
		Erythema	1.93	1.22	3.05	0.005a
Day 29		Erythema	2.06	1.26	3.37	0.004a
Day 57		Erythema	2.03	1.01	4.09	0.047a

Factors predicting the response to ingenol mebutate 0.015% therapy.

^aP < 0.05. OR: Odds ratio; LSR: Local skin reaction.